Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 2Lymphoid 1

Conditions

Multiple Myeloma 75Hodgkin Disease 58Myelodysplastic Syndromes 52Leukemia, Lymphocytic, Chronic, B-Cell 51Lymphoma, Non-Hodgkin 50Precursor Cell Lymphoblastic Leukemia-Lymphoma 49Leukemia, Myeloid, Acute 45Leukemia 41Lymphoma 40Neoplasms, Plasma Cell 38Myeloproliferative Disorders 38Lymphoma, Follicular 38Lymphoma, Mantle-Cell 36Lymphoma, Large B-Cell, Diffuse 35Lymphoma, B-Cell, Marginal Zone 35Burkitt Lymphoma 32Primary Myelofibrosis 30Lymphoma, Large-Cell, Immunoblastic 30Congenital Abnormalities 30Leukemia, Myeloid, Chronic-Phase 28Leukemia, Myeloid, Accelerated Phase 27Leukemia, Myelomonocytic, Chronic 26Blast Crisis 24Waldenstrom Macroglobulinemia 21Lymphoma, T-Cell, Cutaneous 20Sezary Syndrome 19Recurrence 19Mycosis Fungoides 19Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 19Leukemia, Myelogenous, Chronic, BCR-ABL Positive 19

Interventions

fludarabine phosphate 4Dexamethasone 4Peripheral Blood Stem Cell Transplantation 3Melphalan 3pomalidomide 2Whole-Body Irradiation 2Tacrolimus 2Mycophenolic Acid 2ixazomib 1fludarabine 1dexamethasone acetate 1dexamethasone 21-phosphate 1daratumumab 1carmustine, poliferprosan 20 drug combination 1auricularum 1Sirolimus 1RG7388 1Maintenance 1Etoposide 1Cytarabine 1Cyclosporins 1Cyclosporine 1Cyclophosphamide 1Carmustine 1Calcium Dobesilate 1Bortezomib 1Atorvastatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Chromosome 17 deletion × Tacrolimus × Plasma cell × Clear all
NCT01163357 2025-03-26

Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma

City of Hope Medical Center

Phase 1 Completed
18 enrolled
Other hematologic neoplasmPlasma cell

Chromosome 17 deletion, Leukemia, Plasma Cell, Multiple Myeloma

NCT01008462 2019-06-11

Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

Fred Hutchinson Cancer Center

Phase 2 Completed
16 enrolled 15 charts
LymphoidOther hematologic neoplasmPlasma cell

Chromosome 17 deletion, Hodgkin Disease, Leukemia, Plasma Cell, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, T-Cell, Leukemia, Prolymphocytic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡